Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019-11-25
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B06AX07
|
| gptkbp:brand |
gptkb:Oxbryta
|
| gptkbp:CASNumber |
1446321-46-5
|
| gptkbp:chemicalFormula |
C19H15N5O2
|
| gptkbp:developedBy |
gptkb:Global_Blood_Therapeutics
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
voxelotor
|
| https://www.w3.org/2000/01/rdf-schema#label |
Oxbryta
|
| gptkbp:indication |
sickle cell disease
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
hemoglobin S polymerization inhibitor
|
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain fatigue headache rash |
| gptkbp:target |
hemoglobin
|
| gptkbp:bfsParent |
gptkb:Global_Blood_Therapeutics
|
| gptkbp:bfsLayer |
7
|